Argenx Se (ARGX) Gross Margin (2022 - 2026)
Argenx Se's (ARGX) quarterly Gross Margin came in at 90.68% in Q2 2026, up 236.0% YoY from 26.99% in Q2 2025, and little changed on a QoQ basis from 90.68% in Q1 2026.
Argenx Se (ARGX) Gross Margin (2022 - 2026) Analysis & Trends
Argenx Se (ARGX) has 5 years of Gross Margin data on file, last reported at 90.68% in Q2 2026.
- Quarterly Gross Margin rose 236.0% year-over-year to 90.68% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 90.03% (up 64.0% YoY) and the FY2025 annual result came in at 89.39%, down 52.0% from the prior year.
- Gross Margin was little changed at 90.68% in Q2 2026, from 90.68% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 93.52% in Q1 2022 to a low of 88.33% in Q2 2025.
- A 5-year average of 90.5% and a median of 90.22% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin tumbled 317 bps — and 2026, when it soared 236 bps.
- Tracing ARGX's Gross Margin over 5 years: stood at 92.63% in 2022, then slipped by 3 bps to 89.45% in 2023, then gained by 1 bps to 90.14% in 2024, then dropped by 2 bps to 88.36% in 2025, then gained by 3 bps to 90.68% in 2026.
- The last three Gross Margin figures came in at 90.68% (Q2 2026), 90.68% (Q1 2026), and 88.36% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 80.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.68% |
| Mar 31, 2026 | 90.68% |
| Dec 31, 2025 | 88.36% |
| Sep 30, 2025 | 90.29% |
| Jun 30, 2025 | 88.33% |
| Mar 31, 2025 | 89.75% |
| Dec 31, 2024 | 90.14% |
| Sep 30, 2024 | 89.69% |
| Jun 30, 2024 | 89.03% |
| Mar 31, 2024 | 89.16% |
| Dec 31, 2023 | 89.45% |
| Sep 30, 2023 | 89.06% |
| Jun 30, 2023 | 91.08% |
| Mar 31, 2023 | 91.59% |
| Dec 31, 2022 | 92.63% |
| Sep 30, 2022 | 92.18% |
| Jun 30, 2022 | 93.31% |
| Mar 31, 2022 | 93.52% |